Key result
SGLT2 inhibitors lower mean pulmonary artery pressure by ~10 mmHg in PAH models.
Why the study?
Current PAH therapies are mainly vasodilatory, creating a need for treatments targeting additional pathways. Because SGLT2 inhibitors have demonstrated cardiovascular benefits, their effects on pulmonary hemodynamics and right ventricular function in animal models of PAH warranted evaluation.
Do SGLT2 inhibitors improve pulmonary hemodynamics and right ventricular function in preclinical animal models of pulmonary arterial hypertension?
Meta-Analysis
Do SGLT2 inhibitors improve pulmonary hemodynamics and right ventricular function in preclinical animal models of pulmonary arterial hypertension?
In preclinical animal models of pulmonary arterial hypertension, SGLT2 inhibitors significantly improved pulmonary hemodynamics, attenuated right ventricular hypertrophy, and enhanced right ventricular function.
Answers are grounded in this paper and cite their sources.
Preclinical benefits in PAH models do not change practice; leaves open translation to human trials.
Background Pulmonary arterial hypertension (PAH) is a progressive disease marked by vascular remodeling, elevated pulmonary pressures, and right ventricular failure. Current therapies are mainly vasodilatory, underscoring the need for treatments targeting additional pathways. Sodium–glucose cotransporter-2 (SGLT2) inhibitors, initially used for diabetes, have demonstrated cardiovascular benefits. Aims This systematic review and meta-analysis evaluated the effects of SGLT2 inhibitors in animal models of PAH, focusing on pulmonary hemodynamics and right ventricular function. Methods PubMed, Embase, Web of Science, and Scopus were searched for preclinical studies reporting mean pulmonary artery pressure (mPAP), right ventricular systolic pressure (RVSP), right ventricular hypertrophy index (RV/LV+S), tricuspid annular plane systolic excursion (TAPSE), or pulmonary artery acceleration time (PAAT). Random-effects meta-analyses were performed using R. Results Nine studies were included. SGLT2 inhibitors were significantly associated with lower mPAP (WMD −9.79 mmHg), RVSP (WMD −14.81 mmHg), and RV/LV+S (WMD −0.10). They were also associated with higher indices of right ventricular function, including TAPSE (WMD 0.53 mm) and PAAT (WMD 6.39 ms). Conclusion In preclinical models of PAH, SGLT2 inhibitor treatment was associated with favorable hemodynamic and structural parameters. Further research is needed to clarify their translational potential and long-term safety.
No takes yet. Share an insight, caveat, or question.
Qubbaj et al. (2026) conducted a meta-analysis in Pulmonary arterial hypertension (preclinical animal models). Sodium-glucose cotransporter-2 (SGLT2) inhibitors vs. Control (untreated or vehicle-treated PAH animal models) was evaluated on Mean pulmonary artery pressure (mPAP) (WMD -9.79 mmHg). SGLT2 inhibitors reduced mean pulmonary artery pressure and right ventricular systolic pressure in animal models of pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: